Take a breath or take your medication. Read what you write and know that you may need to see a doctor. You're not making sense. If you want to speak to me about etiquette with your slum prudery go right ahead, but you clearly don't have a grasp of your own language, which means you point is not well taken in discussion. Although this is probably not the first time, right, buddy boy?
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.